# "Method Development and Validation for Estimation of Melatonin in Oro- Dispersible Effervescent Tablet By RP-HPLC"

Anchaliya Nilam Pukharaj<sup>1</sup>,Ramakant Sharma<sup>2</sup>, Jeevan Patel<sup>2</sup>,Shabnam khan<sup>2</sup> Amulya Singh Solanki<sup>2</sup>, Priyanka Jain<sup>2</sup> and Dr. Rakesh Patel<sup>3</sup>

1PG Scholar, School of Pharmacy, Dr. A.P. J. Abdul Kalam University, Indore. 2Assistant Professor, School of Pharmacy, Dr. A.P. J. Abdul Kalam University, Indore. 3Professor and Principal, School of Pharmacy, Dr. A.P. J. Abdul Kalam University, Indore.

#### ABSTRACT

In the present research work, successful attempt was made for Estimation MEL in Orodispersible Effervescent tablet using HPLC method. The simplicity, rapidity, reproducibility and economy of proposed method completely fulfil the objective of this research work.HPLC method was developed and validated as per ICH guideline. Developed method was found to be simple, precise and accurate. Using Column C18 Hypersil ODS. The mobile phase was composed of methanol: phosphate Buffer (40:60), detection was done at 223nm. Retention time was found to be 7.1min.There were no methods for estimation of Melatonin in Oro dispersible effervescent tablet. The following method had been developed for estimation of Melatonin in effervescent formulation.Method Development and Validation for Estimation of Melatonin in Effervescent Tablet by RP-HPLC.A new RP-HPLC method was developed for assay of Melatonin in formulation. The separation was achieved on column C18 ODS (Hypersil), 250 nm×4.6 mm, 5 $\mu$ m using methanol: Phosphate Buffer (40:60) use as mobile phase for estimation of Melatonin. Detection was carried out in UV detector at 223 nm.The retention time and total run time was found to be stable at 7.1 min (RT), flow rate1.0 ml, Oven temperature is 25 °C and Injection volume was 20  $\mu$ l.The developed RP-HPLC method was validated for linearity, accuracy, precision, intraday precision, limit of detection and limit of quantitation as per ICH guideline. Developed method was accurate, precise robust and rugged, it showed % RSD not more than 2%.

Keywords: Melatonin, Oro- Dispersible, Effervescent Tablet, RP-HPLC

#### INTRODUCTION

#### 1.1 Analytical Method

Analytical methods development and validation play important roles in the discovery, development, and manufacture of pharmaceuticals. Analytical Chemistry is well-defined as "The science and the art of determining the composition of materials in terms of the elements or compounds contained.<sup>[1]</sup>

- Analytical methods which are amount of quality of the drugs play a very comprehensive role in drug development and follow up activities. It assures that a drug product meets the established standard, is stable and will continue to meet purported quality throughoutits shelf life.<sup>[2]</sup>
- Pharmaceutical analysis plays an important role right from the testing of raw materials; in-process quality checks and analysis of finished products. Pharmaceutical analysis is considered to determine the identity, strength, quality and purity of drug samples.<sup>[3]</sup>
- In analytical chemistry, it is of prime importance to gain information about the qualitative and quantitative compositions of substances and chemical species, that is, to find out what a substance is composed of and exactly how much. In general terms, pharmaceutical analysis comprises of those procedures necessary to determine the "identity, strength, quality and purity" of drugs. Pharmaceutical analysis is a branch of chemistry involving a process of identification, determination, quantification, purification and separation of

components in a mixture or determination of chemical structure of compounds.<sup>[4]</sup> There are two main types of analysis – Qualitative and Quantitative analysis.

1. Qualitative analysis is performed to establish composition of a substance. It is done todetermine the presence of a compound or substance in a given sample or not. The various qualitative tests are detection of evolved gas, limit tests, colour changereactions, determination of melting point and boiling point, mass spectroscopy, determination of nuclear half-life etc.<sup>[5]</sup>

#### Materials and Methods :

#### List of Equipment / Instruments:

The following equipment and instruments have been used in the present studies.

Table			
Name of Instrument	Manufacture		
UV-Visible Spectrophotometer	Shimadzu UV 1800 240V		
HPLC	Agilent 1260 LC infinity		
Ultra Sonicator	Vila Sonicator		
pH meter	Toshcon		
Analytical balance	Aczet		
HPLC Column	Hypersil (250 mm× 4.6 mm)		
HPLC Software	EZ chrome lite		

#### 6.1 Chemicals and Solvents

The following Chemical and Solvents have been used in the present studies

#### **Table No..: Chemicals and Solvents**

Sr.No.	Chemical	Manufactured by
1	HPLC Grade Water	Siddhi Lab
2	Methanol	Rankem
3	Ortho Phosphoric Acid	Rankem
4	Potassium dihydrogen Phosphate	Rankem

#### **EXPERIMENTAL WORK:**

#### **Preparation of Solution:**

**Preparation of Diluent:** 100% Mobile phase

Preparation of Melatonin Standard: Accurately 10 mg Melatonin was weighed and dissolved in 100

ml mobile phase, shook well to mix and sonicated for 5 minutes, filtered through 0.2-micron filter Paper and used filtrate for injection.

**Preparation of Sample solution:** Equivalent to 10 mg Melatonin was weighed form crushed Melatonin tablets powder. Added 30 ml of the mobile phase for 5 minutes, added sufficient of the mobile phase to produce 100 ml. Shook well to mix and sonicated for 5 minutes, filtered through 0.2-micron filter Paper and use filtrate for injection.

Identification of drug: -

- **Melting point determination-** Identification of melting point of MEL was done by using digital melting point determination instrument. Result is mentioned in **Table**
- **Solubility analysis-** Solubility of MEL was checked by dissolving it in number of solvents, like HPLC water, Methanol, Acetonitrile and Buffer. Result is mentioned in
- Fourier transform Infra-red Spectroscopy (FTIR): Infrared absorption spectrum of Melatonin was recorded over the wave number 2000 to 400 cm<sup>-1</sup> using Fourier Transform spectrophotometer (Agilent Technologies). FTIR Spectra is represented in **F**.

Mobile Phase Preparation:

#### • Preparation of phosphate buffer pH 3.0:

Accurately 6.8 gm of Potassium dihydrogen phosphate was weighed and dissolved in 1000 mL of water. The pH was adjusted 3.0 0.02 using Ortho phosphoric acid. The buffer was filtered through 0.22µm filters to remove all fine particles and gases.

Preparation of mobile phase:

The mobile phase was prepared by mixing the buffer and methanol in the ratio of 60:40, sonicated for 5 min. After the solution was filtered through  $0.22 \,\mu m$  to remove all fine particles and gases.

#### METHOD DEVELOPMENT FOR ASSAY

#### 1. Trial 1:

In this trial ACN was selected as a mobile phase and standard Melatonin solution of 10 ppm was prepared in the selected mixture, then chromatogram was recorded afterinjecting the sample in HPLC system. Chromatographic condition mention in **Table** 

II '1 C10
Hypersil C18
Isocratic
ACN
1.5 mL /min
223 nm
10 µL
10 min
25 °C

Table : Chromatographic Condition for Trial 1:

7.6 Analytical Method Validation:

**1. System suitability**: System suitability test are used to verify that the given method of analysis is adequate for the intended analysis.

Procedure: Standard preparation: Make the 10 µg/mL of MEL Stock Solution usingmobile phase.

Acceptance criteria

- 1. The % RSD for the retention times of melatonin Peaks from 5 replicate injections of each Standard solution should be not more than 2.0
- 2. The % RSD for the peak area responses of melatonin peaks from 5 replicate injections of each standard solution should be not more than 2.0%.
- 3. The number of theoretical plates (N) for the melatonin peaks is not less than 2000.

**4.** The Tailing factor (TP) for the Melatonin peak is not more than 2.0.Result of System suitability is mentioned in **Table No.8.4** 

**2. Linearity:** The linearity of analytical procedure is its ability to obtain test results which are directly proportional to the concentration of analyte in sample

• Preparation of standard stock solution

Standard stock solutions of Melatonin  $(100\mu g/mL)$  were prepared by dissolving 10 mg of melatonin in 100 mL of mobile phase. Sonicated for 2 min. further dilutions were given in **Table No.7.5** and Result is mentioned in **Table N** 

7.6 Analytical Method Validation:

**1. System suitability**: System suitability test are used to verify that the given method of analysis is adequate for the intended analysis.

Procedure: Standard preparation: Make the 10 µg/mL of MEL Stock Solution usingmobile phase.

Acceptance criteria

- 5. The % RSD for the retention times of melatonin Peaks from 5 replicate injections of each Standard solution should be not more than 2.0
- 6. The % RSD for the peak area responses of melatonin peaks from 5 replicate injections of each standard solution should be not more than 2.0%.
- 7. The number of theoretical plates (N) for the melatonin peaks is not less than 2000.

**8.** The Tailing factor (TP) for the Melatonin peak is not more than 2.0.Result of System suitability is mentioned in **Table No.8.4** 

**3.** Linearity: The linearity of analytical procedure is its ability to obtain test results which are directly proportional to the concentration of analyte in sample

• Preparation of standard stock solution

Standard stock solutions of Melatonin ( $100\mu g/mL$ ) were prepared by dissolving 10 mg of melatonin in 100 mL of mobile phase. Sonicated for 2 min. further dilutions were given in **Table No.7.5** and Result is mentioned in **Table No.8.5** 

### **3.RESULT AND DISCUSSION:**

Identification of drug: -

Melting point determination:

Table No. 8.1. Result of Wielding Tohit				
Sr.No.	Melting Point			
	Literatrue	Observed		
1	116-118 <sup>0</sup> c	117.6 <sup>°</sup> c		

#### Table No. 8.1: Result of Melting Point

**Discussion-** Melting Point of melatonin was found to 117.6<sup>o</sup>c. That show its Purity.

Solubility Analysis:

Sr.No.	Ingredients	Solubility	
	HPLC Water	Slightly soluble in water	
2	Methanol	Freely Soluble in Methanol	
3	Acetonitrile	Freely solublein Acetonitrile	
4	Buffer (Phosphate buffer pH 3)	Freely solublein Buffer.	

## **Discussion-** From above observation methanol, acetonitrile and buffer showed goodsolubility for melatonin hence Methanol, Acetonitrile and buffer selected as commonsolvent for proper elution in RP-HPLC.

Fourier transform Infra-red Spectroscopy (FTIR):



Fig. 8.1: FTIR Spectra of Melatonin Table No.

Sr.No.	Functional Group	Standard Range (cm-1)	Observed Value (cm-1)
1	N–H bend	1650-1580	1617
2	C=C Stretch	1450-1200	1438
3	C=O stretch	1300-1000	1271
4	C-O stretch	1250-1050	1211,1176
5	C-H bend	860-680	769

#### 8.3: Result of FTIR Spectra

**Discussion-** The Fourier transform infrared spectroscopy (FTIR) spectrum for the pureMelatonin Drug show all Functional group was Present in **Table No.8.3** 

**8.1** Working Wavelength ( $\lambda$ max):



Fig.8.2: UV Spectra of melatonin Discussion:

Working Wavelength of melatonin was reported 223nm.

8.2 Method Development for Assay Trial:

Trial 1:



Fig.8.3: Chromatogram Obtained from Trial 1

#### **Observation:** Improper peak shape

**Discussion:** Due to specificity reason above method cannot be used, further trial to becarried auto proper separation by changing mobile phase composition.

#### 8.3.1 Trial 2 :



**Observation:** Peak observed at retention time 16.060 minute.

**Discussion:** Due to longer retention time above method cannot be used. Further trialsneed to be carried out to shorten retention time.





**Observation:** Peak observed at retention time 15.630 minute.

**Discussion:** Due to longer retention time above method cannot be used. Further trialsneed to be carried out to shorten retention t



Fig.8.6: Chromatogram Obtained from Trial 4

**Observation:** Above peak was found to be satisfactory.

**Discussion:** So, condition of fourth trial were selected as optimised chromatographiccondition. It reduces the cost.

System Suitability: System suitability test are used to verify that the given methodof analysis is adequate for the intended analysis. Results are summarized in Table No.8.4 and chromatogram Represented in Fig 8.7.

Sample No.	Peak area	Asymmetry Factor	Theoretical Plate	Retention Time
Sample 1	22760802	1.25529	6525	7.130
Sample 2	22766171	1.26024	6507	7.127
Sample 3	22760873	1.27385	6493	7.123
Sample 4	22757274	1.26555	6530	7.123
Sample 5	22763060	1.25183	6562	7.123
Mean	22761636	1.261352	6523	7.1252
Std	3274.86			0.0031
% RSD	0.0143	NMT 1.5	NLT 2000	0.044

Table No.8.4: Observation for system suitability



**Chromatogram Obtained from system suitability Conclusion:** The plate count and tailing factor results were found to be satisfactory and are found to be within the limit. The % RSD was found to be 0.0143.

**Discussion:** System suitability solution was found within the limit so that the givenprocedure of analysis is suitable on above mentioned chromatographic conditions.

Linearity:

Conc. (PPM)	AREA
2	5241704
4	10288305
6	15460269
8	20508193
10	26713649
12	30504235
SLOPE	2580523.014
Y- INTERCEPT	55731.4
COREELATION	0.9988



Fig.8.8: Graph of linearity

#### Acceptance criteria:

The correlation coefficient is not less than 0.99.

Conclusion:

The correlation coefficient for linear curve obtained between concentration vs. Area forstandard preparations of melatonin was found to be 0.998 respectively.

Discussion: The observed values were within the acceptance criteria. The Graph oflinearity show the linear.

#### **8.4.3.** Precision:

A. Repeatability:



Sample	% Assay
Sample 1	99.22
Sample 2	98.73
Sample 3	98.81
Sample 4	98.62
Sample 5	98.79
Sample 6	98.61
Mean	98.80
Std Dev.	0.2235
%RSD	0.2263

#### **Conclusion:**

- 1. Assay of melatonin sample was found in the limit.
- 2. As per acceptance criteria RSD of % assay of six samples is NMT 2.0 % it comes0.22%.

#### **B.** Intermediate precision:

Table No.	8.7:	Observation	for	Intermediate	Precision
1 and 1 10.	0.7.	Obser valion	101	munitulate	I I COBIOII

Days	Sample	% Assay of
		Melatonin
	Sample-1	98.39
Day	Sample-2	99.05
1	Sample-3	98.55
	Average	98.66
	Std Dev.	0.344287
	% RSD	0.3489
	Sample-1	100.25
Dav	Sample-2	99.69
2	Sample-3	98.77
	Average	99.57
	Std Dev.	0.747262
	% RSD	0.7504

Conclusion:

- 1. Assay of Melatonin sample was found in the limit.
- 2. % RSD of Assay was within limit i.e., NMT 2.0%

**Discussion**- From the above data and assays are within specified limits, which indicates that the procedure for analysis was precises for the given set of chromatographic conditions.

Assay Spl 1	80.50	98.36	122.56
Assay Spl 2	80.63	98.28	122.05
Assay Spl 3	81.09	98.49	121.10

Vol-9 Issue-5 2023

Mean % Assay	80.74	98.37	121.90
% Recovery	100.62	98.36	102.1
Spl 1			
% Recovery	100.78	98.28	101.70
Spl 1			
% Recovery	101.36	98.49	100.91
Spl 1			
Mean % Recovery	100.92	98.37	101.58
SD	0.3179	0.08653	0.4944
%RSD	0.315	0.08797	0.4867





#### Observation for Placebo

Limit of detection (LOD) and Limit of Quantification (LOQ):

Parameters	Result
SD of intercept	15133.77
Slope	2580523.01
LOD (µg/mL)	0.019µg/mL
LOQ (µg/mL)	0.058µg/mL

Discussion: From the above observation LOD and LOQ was found  $0.019\mu$ g/mL and  $0.058\mu$ g/mL.

Specificity and Placebo study:

#### • Placebo sample:

Sample of placebo was weighted and transferred into volumetric flask. Volume was madewith mobile phase.

Sample No.	Wt. taken. (Placebo) gm	Peak area	% Assay
Placebo 1	0.135	N.D.	
Placebo 2	0.135	N.D.	
Placebo 3	0.135	N.D.	

Table No	.8.10:	Observation	for	Placebo
1 4010 1 10	.0.10.	000001 fution	101	I Ideecoo

Mean		
	-	
Std Dev.		
	-	
% RSD		
	-	

#### References

- 1. Kasture A.V., Wadodkar S. G., K. R. Mahadik., H. N. More., "PharmaceuticalAnalysis", Nirali Prakashan ,2016; 2 (23):2.1- 2.2.
- 2. Chatten LG, "Pharmaceutical chemistry" Marcel Dekker Inc, 1996; 2:23-25.
- 3. Beckett AH, Stenlake JB, "Practical pharmaceutical chemistry", CBS publisherand distributors, 1986;2:13-17.
- 4. David CL, "Pharmaceutical analysis", Black well publishing, 1994;6:2-4.
- 5. Ahuja S, "Handbook of modern pharmaceutical analysis", Eds.Academic Press, 2001; 3 : 383.
- 6. Basic Education in Analytical Chemistry, Analytical Science, 2001:17
- 7. Ohannesian L, Streeter J.A., "Drugs and pharmaceutical science", Handbook ofpharmaceutical Analysis, 130-149
- 8. Douglas A; Skoog F; james , H.stanley, "Liquid chromatography in instrumentalanalysis", Cengage learning India pvt.ltd;2007;9:893-934
- 9. Solvent delivery systemhttp://www.monozirpal.net/instrumenatal%20Analysis/lecture/Lectures%2021-/239pdf(07-01-2021)

10.injection valves

http://www.dolomitemicrofluidics.com/webshop/flowaccessoriesinjection-valvesc17\_18/sample-injection-valvu-p-783(07-01-2021)

11. Malviya R, Bansal V, Pal O.P. and Sharma P.K, "High Performance Liquid Chromatography: A SHORT REVIEW", Journal of Global Pharma Technology.2010; 2(5): 22-23.

12. Verma Vikrant, "A Review on HPLC and RP-HPLC Analysis Method" International Journal of institutional pharmacy and life sciences, 2014;4(4):50-64.

- 13. Mr. Gorhe S G, Miss. Pawar G R, "A Review on High Performance Liquid Chromatography (HPLC)", International Journal Of Advance Scientific Research And Engineering Trends, 2018; 3(1):6-7.
- 14. Santosh Kumar Bhardwaj, K. Dwivedia and D. D. Agarwala, "A Review: HPLCMethod Development and Validation", International Journal of Analytical and Bioanalytical Chemistry, 2015; 5(4), 76-7

21524